Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice

Vaccine

Volumn 24, Issue 35-36, 2006, Pages 6065-6073

  Wang, Guiyun ^a   Sun, Meiyan ^a   Fang, Jinbo ^a   Yang, Qiong ^a   Tong, Haibin ^a   Wang, Li ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

Bacteriophage display; Immune responses; Specific epitope of Candida albicans HSP90

Indexed keywords

CONCANAVALIN A; EDETIC ACID; HEAT SHOCK PROTEIN 90; TROMETAMOL;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL PROLIFERATION; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PH; PHAGE DISPLAY; PRIORITY JOURNAL; SPLEEN CELL; WILD TYPE;

ANIMALS; ANTIBODY SPECIFICITY; BACTERIOPHAGE M13; CANDIDA ALBICANS; CANDIDIASIS; CELL PROLIFERATION; CONCANAVALIN A; EPITOPES, B-LYMPHOCYTE; HSP90 HEAT-SHOCK PROTEINS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; SPLEEN;

EID: 33747031173     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.022     Document Type: Article

References (55)

1. Ashman R.B., Papadimitriou J.M., Ott A.K., and Warmington J.R. Antigens and immune responses in Candida albicans infection. Immunol Cell Biol 68 Part 1 (1990) 1-13
2. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42 4 (2004) 1519-1527
3. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., and Jones R.N. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 48 2 (2004) 101-105
4. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 9 (2003) 1172-1177
5. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 3 (2001) 358-366
6. Richardson M.D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 Suppl. 1 (2005) i5-i11
7. Clark T.A., and Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 15 6 (2002) 569-574
8. Krcmery V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50 4 (2002) 243-260
9. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., Jones R.N., et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 41 1 (2003) 78-83
10. Romani L. Immunity to candida. albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 2 4 (1999) 363-367
11. +-T-cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans. Antimicrob Agents Chemother 44 10 (2000) 2653-2658
12. Matthews R.C., Burnie J.P., Howat D., Rowland T., and Walton F. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74 1 (1991) 20-24
13. Maiti P.K., Kumar A., Kumar R., and Mohapatra L.N. Role of antibodies and effect of BCG vaccination in experimental candidiasis in mice. Mycopathologia 91 2 (1985) 79-85
14. Wagner R.D., Vazquez-Torres A., Jones-Carson J., Warner T., and Balish E. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 174 3 (1996) 589-597
15. Matthews R.C., Burnie J.P., and Tabaqchali S. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol 25 2 (1987) 230-237
16. Han Y., and Cutler J.M. Antibody response that protects against disseminated candidiasis. Infect Immun 63 7 (1995) 2714-2719
17. Huffnagle G.B., and Deepe G.S. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr Opin Microbiol 6 4 (2003) 344-350
18. Lehner T. Serum fluorescent antibody and immunoglobulin estimations in candidosis. J Med Microbiol 3 3 (1970) 475-481
19. Yuan R., Casadevall A., Spira G., and Scharff M.D. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 154 4 (1995) 1810-1816
20. + cells also demonstrate strain-specific immunopathological effects. Microbiology 145 Part 7 (1999) 1631-1640
21. Cenci E., Romani L., Vecchiarelli A., Puccetti P., and Bistoni F. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol 144 11 (1990) 4333-4339
22. Coker III L.A., Mercadal C.M., Rouse B.T., and Moore R.N. Differential effects of CD4+ and CD8+ cells in acute, systemic murine candidosis. J Leukoc Biol 51 3 (1992) 305-306
23. Balish E., Vazquez-Torres F.A., Jones-Carson J., Wagner R.D., and Warner T. Importance of beta2-microglobulin in murine resistance to mucosal and systemic candidiasis. Infect Immun 64 12 (1996) 5092-5097
24. Beno D.W., Stove A.G., and Matthews H.L. Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes. J Immunol 154 10 (1995) 5273-5281
25. Levitz S.M. Overview of host defenses in fungal infections. Clin Infect Dis 14 Suppl. 1 (1992) S37-S42 [Review]
26. Polonelli L., Casadevall A., Han Y., Bernardis F., Kirkland T.N., Matthews R.C., et al. The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Med Mycol 38 Suppl. 1 (2000) 281-292
27. Burnie J.P., and Matthews R.C. The role of antibodies against hsp90 in the treatment of fungal infections. Drug News Perspect 16 4 (2003) 205-210
28. Matthews R.C., and Burnie J.P. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med 5 4 (2005) 403-411
29. Matthews R.C., and Burnie J.P. Antibodies against Candida: potential therapeutics?. Trends Microbiol 4 9 (1996) 354-358
30. Matthews R., Burnie J.P., and Lee W. The application of epitope mapping in the development of a new serological test for systemic candidosis. J Immunol Methods 143 1 (1991) 73-79
31. Matthews R.C., Burnie J.P., and Tabaqchali S. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol 25 2 (1987) 230-237
32. Matthews R.C., Burnie J.P., Howat D., Rowland T., and Walton F. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74 1 (1991) 20-24
33. Matthews R.C., Burnie J.P., and Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet 2 8417-18 (1984) 1415-1418
34. Matthews R.C., and Burnie J.P. The role of HSP90 in fungal infection. Immunol Today 13 9 (1992) 345-348
35. Yang Q., Wang L., Lu D.N., Gao R.J., Song J.N., Hua P.Y., et al. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Vaccine 23 31 (2005) 4088-4096
36. Matthews R.C., Hodgetts S., and Burnie J. Preliminary assessment of a human recombinant antibody fragment to HSP90 in murine invasive candidiasis. J Infect Dis 171 6 (1995) 1668-1671
37. De Berardinis P., Sartorius R., Fanutti C., Perham R.N., Del Pozzo G., and Guardiola J. Phage display of peptide epitopes from HIV-1 elicits cytolytic responses. Nat Biotechnol 18 8 (2000) 873-876
38. De Berardinis P., D'Apice L., Prisco A., Ombra M.N., Barba P., Del Pozzo G., et al. Recognition of HIV-derived B and T cell epitopes displayed on filamentous phage. Vaccine 17 11-12 (1999) 1434-1441
39. Fulvia D.M.V., Anne E.W., Cynthia B.T., Ettore A., and Richard N.P. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage: the V3 loop of HIV-1 gp120. J Mol Biol 243 2 (1994) 167-172
40. Richard N.P., Tammsin D.T., Anne E.W., Judith G., Fulvia di M.V., and Ettore A. Engineering a peptide epitope display system on filamentous bacteriophage. FEMS Microbiol Rev 17 1-2 (1995) 25-31
41. Wang L., and Wang G.Y. Vectors for foreign peptides display on the surface of the major coat protein of filamentous phage. J Mol Sci 16 3 (2000) 184-187
42. Malik P., Terry T.D., Gowda L.R., Langara A., Petukhov S.A., Symmons M.F., et al. Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. J Mol Biol 260 1 (1996) 9-21
43. Schagger H., and Von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166 2 (1987) 368-379
44. Fang J.B., Wang G.Y., Yang Q., Song J.N., Wang Y., and Wang L. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23 40 (2005) 4860-4866
45. Seder R.A., and Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12 (1994) 635-673
46. Biron C.A. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 6 4 (1994) 530-538
47. Fearon D.T., and Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 272 5258 (1996) 50-53
48. Klein E., and Mantovani A. Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 5 5 (1993) 714-718
49. Djeu J.Y., Blanchard D.K., Richards A.L., and Friedman H. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol 141 11 (1988) 4047-4052
50. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., and Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT (R192G), against systemic candidiasis. Infect Immun 67 2 (1999) 826-833
51. Gaubin M., Fanutti C., Mishal Z., Durrbach A., De Berardinis P., Sartorius R., et al. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 22 1 (2003) 11-18
52. Minenkova O.O., Ilyichev A.A., Kishchenko G.P., and Petrenko V.A. Design of specific immunogens using filamentous phage as the carrier. Gene 128 1 (1993) 85-88
53. Willis A.E., Perham R.N., and Wraith D. Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene 128 1 (1993) 79-83
54. Piergiuseppe D.B., Rossella S., Cristina F., Richard N.P., Giovanna D.P., and John G. Phage display of peptide epitopes from HIV-1 elicites strong cytolytic responses. Nat Biotechnol 18 8 (2000) 873-876
55. Wan Y., Wu Y., Bian J., Wang X.Z., Zhou W., Jia Z.C., et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine 19 20-22 (2001) 2918-2923